Parkinson's disease (PD) is one of the most prevalent neurodegenerative disease
displaying negative impacts on both the health and social ability of patients and …

The quest for a non-dopaminergic approach to treating Parkinson's disease (PD) has been
quietly progressing over the past several decades, and is now finding its momentum. Here …

Parkinson's disease (PD) is a neurodegenerative disease characterized pathologically by α-
synuclein (α-syn) aggregation. In PD, the current mainstay of symptomatic treatment is …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder,
affecting up to 10 million people worldwide. Current treatment primarily involves symptom …

Adenosine A 2A receptor antagonists represent a new way forward in the symptomatic
treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class …

Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder. To
date, most of the currently available therapies in PD target the dopaminergic system and …

Parkinson's disease (PD) is a neurodegenerative disease with significant unmet medical
needs. The current dopamine-centered treatments aim to restore motor functions of patients …

Parkinson's disease (PD) is a common, debilitating neurodegenerative disorder that creates
a significant burden for patients, family members and society at large. Major unmet needs …

The adenosine A 2A receptor has emerged as an attractive non-dopaminergic target in the
pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS …

Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the
physiological functions of adenosine. In the central nervous system adenosine A2A …